These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36109321)

  • 1. A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell-derived allogeneic cell therapies.
    Dashnau JL; Xue Q; Nelson M; Law E; Cao L; Hei D
    Cytotherapy; 2023 Jan; 25(1):1-13. PubMed ID: 36109321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioprocessing considerations for generation of iPSCs intended for clinical application: perspectives from the ISCT Emerging Regenerative Medicine Technology working group.
    Song HW; Solomon JN; Masri F; Mack A; Durand N; Cameau E; Dianat N; Hunter A; Oh S; Schoen B; Marsh M; Bravery C; Sumen C; Clarke D; Bharti K; Allickson JG; Lakshmipathy U
    Cytotherapy; 2024 May; ():. PubMed ID: 38970614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status.
    Awe JP; Lee PC; Ramathal C; Vega-Crespo A; Durruthy-Durruthy J; Cooper A; Karumbayaram S; Lowry WE; Clark AT; Zack JA; Sebastiano V; Kohn DB; Pyle AD; Martin MG; Lipshutz GS; Phelps PE; Pera RA; Byrne JA
    Stem Cell Res Ther; 2013 Jul; 4(4):87. PubMed ID: 23890092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges.
    Madrid M; Sumen C; Aivio S; Saklayen N
    Curr Protoc; 2021 Mar; 1(3):e88. PubMed ID: 33725407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation.
    Sackett SD; Brown ME; Tremmel DM; Ellis T; Burlingham WJ; Odorico JS
    Transplant Rev (Orlando); 2016 Apr; 30(2):61-70. PubMed ID: 26970668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.
    Jha BS; Farnoodian M; Bharti K
    Stem Cells Transl Med; 2021 Feb; 10(2):198-208. PubMed ID: 32946199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc finger nuclease-expressing baculoviral vectors mediate targeted genome integration of reprogramming factor genes to facilitate the generation of human induced pluripotent stem cells.
    Phang RZ; Tay FC; Goh SL; Lau CH; Zhu H; Tan WK; Liang Q; Chen C; Du S; Li Z; Tay JC; Wu C; Zeng J; Fan W; Toh HC; Wang S
    Stem Cells Transl Med; 2013 Dec; 2(12):935-45. PubMed ID: 24167318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of Human Induced Pluripotent Stem Cell-Derived Bona Fide Neural Stem Cells for Ex Vivo Gene Therapy of Metachromatic Leukodystrophy.
    Meneghini V; Frati G; Sala D; De Cicco S; Luciani M; Cavazzin C; Paulis M; Mentzen W; Morena F; Giannelli S; Sanvito F; Villa A; Bulfone A; Broccoli V; Martino S; Gritti A
    Stem Cells Transl Med; 2017 Feb; 6(2):352-368. PubMed ID: 28191778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using an integration free vector.
    Rossbach B; Hildebrand L; El-Ahmad L; Stachelscheid H; Reinke P; Kurtz A
    Stem Cell Res; 2016 Mar; 16(2):314-7. PubMed ID: 27345993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease.
    Son MY; Lee MO; Jeon H; Seol B; Kim JH; Chang JS; Cho YS
    Exp Mol Med; 2016 May; 48(5):e232. PubMed ID: 27174201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platforms for Manufacturing Allogeneic, Autologous and iPSC Cell Therapy Products: An Industry Perspective.
    Abraham E; Ahmadian BB; Holderness K; Levinson Y; McAfee E
    Adv Biochem Eng Biotechnol; 2018; 165():323-350. PubMed ID: 28534167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an induced pluripotent stem cell-specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products.
    Chung L; Cogburn LA; Sui L; Dashnau JL
    Cytotherapy; 2022 Jul; 24(7):733-741. PubMed ID: 35461759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Umbilical Cord Tissue as a Source of Young Cells for the Derivation of Induced Pluripotent Stem Cells Using Non-Integrating Episomal Vectors and Feeder-Free Conditions.
    Mohamed A; Chow T; Whiteley J; Fantin A; Sorra K; Hicks R; Rogers IM
    Cells; 2020 Dec; 10(1):. PubMed ID: 33396312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells.
    Shafa M; Walsh T; Panchalingam KM; Richardson T; Menendez L; Tian X; Suresh Babu S; Dadgar S; Beller J; Yang F; Baghbaderani BA
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent Stem Cell-Derived Allografts.
    Sasaki H; Wada H; Baghdadi M; Tsuji H; Otsuka R; Morita K; Shinohara N; Seino K
    Transplantation; 2015 Nov; 99(11):2301-10. PubMed ID: 26360665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogramming Methods Do Not Affect Gene Expression Profile of Human Induced Pluripotent Stem Cells.
    Trevisan M; Desole G; Costanzi G; Lavezzo E; Palù G; Barzon L
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A synthetic mRNA cell reprogramming method using CYCLIN D1 promotes DNA repair, generating improved genetically stable human induced pluripotent stem cells.
    Alvarez-Palomo AB; Requena-Osete J; Delgado-Morales R; Moreno-Manzano V; Grau-Bove C; Tejera AM; Otero MJ; Barrot C; Santos-Barriopedro I; Vaquero A; Mezquita-Pla J; Moran S; Naya CH; Garcia-Martínez I; Pérez FV; Blasco MA; Esteller M; Edel MJ
    Stem Cells; 2021 Jul; 39(7):866-881. PubMed ID: 33621399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. History and current status of clinical studies using human pluripotent stem cells.
    Kobold S; Bultjer N; Stacey G; Mueller SC; Kurtz A; Mah N
    Stem Cell Reports; 2023 Aug; 18(8):1592-1598. PubMed ID: 37028422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
    Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
    Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copy number variant hotspots in Han Taiwanese population induced pluripotent stem cell lines - lessons from establishing the Taiwan human disease iPSC Consortium Bank.
    Huang CY; Li LH; Hsu WT; Cheng YC; Nicholson MW; Liu CL; Ting CY; Ko HW; Syu SH; Wen CH; Yan Z; Huang HP; Su HL; Chiang PM; Shen CN; Chen HF; Yen BLJ; Lu HE; Hwang SM; Chiou SH; Ho HN; Wu JY; Kamp TJ; Wu JC; Hsieh PCH
    J Biomed Sci; 2020 Sep; 27(1):92. PubMed ID: 32887585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.